The Role of Epidemic Tumor Vaccine in Cold Tumors to Hot Tumors

Abstract

Compared with hot tumors, cold tumors are a more difficult problem at present. Because cold tumors lack in congenital immunity, it is difficult for ordinary immune examination inhibitors to work. Therefore, how to "ignite" cold tumors as hot tumors is the focus of the current research. At present, scholars have proposed different and corresponding methods for various causes of T cell immunodeficiency. Among them, tumor vaccines stand out from the principle of activating the immune response of T cells and NK cells, and is currently generally recognized as a new therapy and research hotspot with strong anti-cancer activity. By classifying the target sites of tumor vaccines, they can be divided into tumor-related antigen (TAAs) vaccines and new antigen (TSAs) vaccines. Both vaccines have shown significant effects in activating T cells and NK cells. In terms of the current development status of the two vaccines, more and more research teams have invested in the research of TSAs vaccines, and many teams still insist on the research of TAAs vaccines. Although these two vaccines have their own difficulties to overcome, they still have made great contributions to the development of tumor treatment research, and both have advantages and broad prospects that cannot be reached by other methods. It is believed that no more effective tumor vaccines have been put into clinical trials.